PubMed

Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial.

Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A.

Diabetes Care. 2007 Nov;30(11):2804-10. Epub 2007 Aug 8.PMID: 17686832 [PubMed - indexed for MEDLINE]Related articlesFree article

Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes.

Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, Atkin SL.

Diabetes Care. 2002 Oct;25(10):1709-14.PMID: 12351466 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes.

Jenkins DJ, Kendall CW, Augustin LS, Martini MC, Axelsen M, Faulkner D, Vidgen E, Parker T, Lau H, Connelly PW, Teitel J, Singer W, Vandenbroucke AC, Leiter LA, Josse RG.

Diabetes Care. 2002 Sep;25(9):1522-8.PMID: 12196421 [PubMed - indexed for MEDLINE]Related articlesFree article

Chia seed does not promote weight loss or alter disease risk factors in overweight adults.

Nieman DC, Cayea EJ, Austin MD, Henson DA, McAnulty SR, Jin F.

Nutr Res. 2009 Jun;29(6):414-8.PMID: 19628108 [PubMed - indexed for MEDLINE]Related articles

Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects.

Hermansen K, Søndergaard M, Høie L, Carstensen M, Brock B.

Diabetes Care. 2001 Feb;24(2):228-33.PMID: 11213870 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension.

Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ.

Am J Clin Nutr. 2002 Nov;76(5):1007-15.PMID: 12399272 [PubMed - indexed for MEDLINE]Related articlesFree article

Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial.

Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C.

Diabetes Care. 1999 Jun;22(6):913-9.PMID: 10372241 [PubMed - indexed for MEDLINE]Related articlesFree article

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.

Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D, Henderson W; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2.

J Diabetes Complications. 2003 Nov-Dec;17(6):314-22.PMID: 14583175 [PubMed - indexed for MEDLINE]Related articles

Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.

Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U.

Diabetes Care. 1991 Apr;14(4):308-17.PMID: 2060433 [PubMed - indexed for MEDLINE]Related articles

Insulin therapy, glycemic control, and cardiovascular risk factors in young Latin Americans with type 2 diabetes mellitus.

Avilés-Santa L, Salinas K, Adams-Huet B, Raskin P.

J Investig Med. 2006 Jan;54(1):20-31.PMID: 16409887 [PubMed - indexed for MEDLINE]Related articles

Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.

Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD.

Neth J Med. 2003 Apr;61(4):129-36.PMID: 12852722 [PubMed - indexed for MEDLINE]Related articlesFree article

A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

[Pharmacological therapy of obesity]

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort.

Jenkins AJ, Rothen M, Klein RL, Moller K, Eldridge L, Zheng D, Durazo-Arvizu R, McGee D, Lackland D, Thorpe SR, Garvey WT, Lyons TJ; DCCT/EDIC Research Group.

J Diabetes Complications. 2008 May-Jun;22(3):153-63. Epub 2008 Apr 16.PMID: 18413218 [PubMed - indexed for MEDLINE]Related articles

Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.

Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM.

Circulation. 2005 May 17;111(19):2446-53. Epub 2005 May 2.PMID: 15867184 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.

Madsen T, Schmidt EB, Christensen JH.

J Ren Nutr. 2007 Jul;17(4):258-63.PMID: 17586424 [PubMed - indexed for MEDLINE]Related articles

Impact of physical activity on cardiovascular risk factors in IDDM.

Lehmann R, Kaplan V, Bingisser R, Bloch KE, Spinas GA.

Diabetes Care. 1997 Oct;20(10):1603-11.PMID: 9314643 [PubMed - indexed for MEDLINE]Related articles

Vitamin C intake and cardiovascular disease risk factors in persons with non-insulin-dependent diabetes mellitus. From the Insulin Resistance Atherosclerosis Study and the San Luis Valley Diabetes Study.

Mayer-Davis EJ, Monaco JH, Marshall JA, Rushing J, Juhaeri.

Prev Med. 1997 May-Jun;26(3):277-83.PMID: 9144749 [PubMed - indexed for MEDLINE]Related articles

The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus.

Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, Alevizos M.

Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):837-43.PMID: 18043308 [PubMed - indexed for MEDLINE]Related articles

Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.

Wagner H, Degerblad M, Thorell A, Nygren J, Ståhle A, Kuhl J, Brismar TB, Ohrvik J, Efendic S, Båvenholm PN.

Diabetes Care. 2006 Jul;29(7):1471-7.PMID: 16801564 [PubMed - indexed for MEDLINE]Related articlesFree article